IRIS

ASCIERTO, PAOLO ANTONIO

ASCIERTO, PAOLO ANTONIO  

DIPARTIMENTO DI NEUROSCIENZE E SCIENZE RIPRODUTTIVE ED ODONTOSTOMATOLOGICHE  

Mostra records
Risultati 1 - 20 di 590 (tempo di esecuzione: 0.008 secondi).
Titolo Tipologia Data di pubblicazione Autore(i) File
Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma 1.1 Articolo in rivista 2008 Ascierto, P
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma 1.1 Articolo in rivista 2014 Larkin, J; Ascierto, P; Dreno, B; Atkinson, V; Liszkay, G; Maio, M; Mandala, M; Demidov, L; Stroyakovskiy, D; Thomas, L; de la Cruz-Merino, L; Dutriaux, C; Garbe, C; Sovak, Ma; Chang, I; Choong, N; Hack, Sp; Mcarthur, Ga; Ribas, A
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-alpha in advanced malignant melanoma 1.1 Articolo in rivista 2013 Ascierto, P
Prognostic value of serum VEGF in melanoma patients: a pilot study 1.1 Articolo in rivista 2004 Ascierto, P
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma 1.1 Articolo in rivista 2013 Ascierto, P; Minor, D; Ribas, A; Lebbe, C; O'Hagan, A; Arya, N; Guckert, M; Schadendorf, D; Kefford, Rf; Grob, Jj; Hamid, O; Amaravadi, R; Simeone, E; Wilhelm, T; Kim, Kb; Long, Gv; Martin, Am; Mazumdar, J; Goodman, Vl; Trefzer, U
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4(+)CD25(++)Foxp3(+) regulatory T-cells in advanced melanoma patients 1.1 Articolo in rivista 2013 Ascierto, P
The role of BRAF V600 mutation in melanoma 1.1 Articolo in rivista 2012 Ascierto, P
Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice 1.1 Articolo in rivista 2015 Ascierto, P
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 1.1 Articolo in rivista 2014 Ascierto, P
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial 1.1 Articolo in rivista 2012 Ascierto, P
Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters 1.1 Articolo in rivista 2004 Ascierto, P
Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma 1.1 Articolo in rivista 2006 Palmieri, G; Satriano, Smr; Budroni, M; Cossu, A; Tanda, F; Canzanella, S; Caraco, C; Simeone, E; Daponte, A; Mozzillo, N; Comella, G; Castello, G; Ascierto, P
Molecular Pathogenesis of Melanoma: Established and Novel Pathways 2.1 Contributo in volume (Capitolo o Saggio) 2012 Ascierto, P; Ascierto, Ml; Capone, M; Elaba, Z; Murphy, Mj; And Palmieri, G
The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients 1.1 Articolo in rivista 2010 Ascierto, P
Combination therapy: the next opportunity and challenge of medicine 1.1 Articolo in rivista 2011 Ascierto, P
Combination therapy: the next opportunity and challenge of medicine 1.1 Articolo in rivista 2011 Ascierto, P; Marincola, Fm
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies 1.1 Articolo in rivista 2010 Ascierto, P; Simeone, E; Sznol, M; Fu, Yx; Melero, I
Defining the critical hurdles in cancer immunotherapy 1.1 Articolo in rivista 2011 Ascierto, P
Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies 1.1 Articolo in rivista 2005 Ascierto, P
Microenvironment and tumor progression of melanoma: New therapeutic prospectives 1.1 Articolo in rivista 2013 Ascierto, P